All Biomarkers articles
-
ArticleWhat makes a human biospecimen fit for purpose in drug discovery
Human biospecimens can bring drug discovery closer to human disease, but their value depends on far more than the sample itself. We explore the factors that determine how much researchers can learn from them.
-
WebinarMapping the prostate tumour microenvironment with spatial proteomics
As spatial proteomics advances, how can researchers find the complex biology of the prostate tumour microenvironment while preserving spatial context? Hear experts from the University of Surrey share their approach.
-
ArticleWhy depression needs a different drug discovery strategy
What if depression is not one disease, but many biologically distinct conditions? A major research programme is investigating what this could mean for biomarkers, drug targets and treatment.
-
NewsNew LOX target discovery could help overcome chemotherapy-resistant breast cancer
A preclinical study has identified lysyl oxidase as an intracellular survival factor in triple-negative breast cancer, with researchers demonstrating that sequentially blocking LOX and a compensatory ferroptosis defence pathway significantly suppresses tumour growth without chemotherapy.
-
WebinarFrom antibody discovery to development: long-read sequencing in practice
As sequencing continues to grow in importance across biotherapeutic discovery and development, where can it make the biggest impact and how can fragmented workflows be overcome?
-
NewsBlood metabolite links ALS progression rate to potential treatment target
A metabolic signal detectable in patient blood has been linked to ALS progression rate and survival, with preclinical data suggesting that boosting levels of the molecule could protect motor neurons and extend survival in disease models.
-
WebinarWhat it really takes to turn cancer discoveries into new therapies
Five leading cancer researchers from across genomics, proteomics, cell biology, chemical biology and gene therapy dig into what’s driving cancer drug discovery forward and what’s still holding progress back.
-
ReportBuilding biomarkers that drug developers can rely on
Discover how integrated technologies, multiomic approaches and AI are helping researchers translate complex biological signals into actionable tools for drug development and patient care.
-
ArticleHow rare genetic variants could uncover new drug targets
What if extreme levels of common traits have a different genetic basis? New research suggests rare, large-effect variants could help explain the extremes and identify potential drug targets.
-
NewsHER3-DXd and olaparib combination boosts lung cancer treatment responses
A new preclinical study finds that combining the antibody-drug conjugate HER3-DXd with PARP inhibitor olaparib significantly improves treatment responses in NSCLC models, including those harbouring EGFR and KRAS mutations, by overwhelming DNA repair capacity and activating innate immune signalling.
-
NewsFirst-in-class drug targets ‘undruggable’ MYC in blood cancers
A first-in-class experimental drug has demonstrated preclinical activity against treatment-resistant blood cancers by exploiting a newly identified vulnerability between MYC and GSPT1, offering a potential route to one of oncology’s most elusive targets.
-
ArticleHow AI-driven systems biology will reset the starting line for drug development
AI is making drug discovery faster, but can it make it more successful? Discover why combining AI with systems biology could help researchers tackle the biological complexity behind drug failure.
-
NewsIL-17 identified as potential immunotherapy biomarker in ovarian cancer
A new study has identified IL-17 as a potential biomarker for immunotherapy response in a small subset of clear cell ovarian cancer cases, offering a possible route to personalised treatment for a disease historically resistant to immune-based therapies.
-
ArticleWhy researchers are revisiting bisantrene decades after it was abandoned
An oncology drug abandoned decades ago is getting a second look, with new research uncovering a mechanism that could offer an alternative route to targeting MYC, one of cancer’s toughest targets.
-
NewsNUS researchers identify molecular switch driving TNBC treatment resistance
Researchers at the National University of Singapore have identified DP103 as a potential molecular master switch sustaining tumour growth, cancer stem cells and treatment resistance in triple-negative breast cancer, with findings suggesting it could serve as a predictive biomarker for the investigational oral therapy RX-5902.
-
NewsPatient-specific brain tumour chip models vascular drug barriers
A microfluidic chip combining patient-derived glioblastoma cells with their tumour vascular environment could give drug developers a more realistic preclinical model for predicting treatment response – and may help explain why genetically similar patients respond differently to the same therapy.
-
NewsAGR2 and FOXM1 identified as prognostic and therapeutic targets in NF-PanNETs
A new study using single-cell RNA sequencing has identified AGR2 as a potential prognostic marker and FOXM1 as a druggable target in non-functional pancreatic neuroendocrine tumours, offering new tools to stratify patients and guide treatment strategies.
-
NewsAutomated MRI pipeline standardises preclinical stroke damage measurement
An automated imaging pipeline developed at USC’s Stevens Neuroimaging and Informatics Institute can measure stroke-related brain tissue damage from MRI scans with accuracy matching human experts, offering a scalable, standardised tool for preclinical drug evaluation across multi-site research networks.
-
ArticleFibroblast barrier linked to immunotherapy resistance in colorectal cancer
Why do some colorectal cancers resist immunotherapy? Analysis of patient tumour samples has identified a population of fibroblasts that could help explain treatment resistance.
-
NewsHow CAR T cells are being engineered to target tumour’s ‘soft spot’
A preclinical study published in Nature Biomedical Engineering describes a synthetic biology approach that converts the physical softness of cancer cells into a targetable signal for CAR-T immunotherapy, potentially addressing a key resistance mechanism in solid tumours.